IgA肾病治疗迎长效时代:大冢制药斯贝利单抗获FDA加速批准,布地奈德仿制市场潜力巨大

摩熵医药
Dec 02

11月26日,大冢制药宣布,其创新药物斯贝利单抗(Voyxact)已获得FDA加速批准,用于治疗有疾病进展风险的原发性免疫球蛋白A肾病(IgAN)成人患者,以显著减少蛋白尿,能实现1月给药一次。由此,IgA肾病治疗药物步入了长效给药研发阶段。今年8月和9月,诺华的阿曲生坦和伊普可泮分别在国内获批用于IgA肾病,同时期,国内荣昌生物的泰它西普拟纳入优先审评品种,用于治疗具有进展风险的原发性免疫球蛋白...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10